Research profile

The focus of BREATH is the translation of findings from basic research into clinical practice, taking into account all topics listed below. This includes carrying out clinical studies of all phases relevant for registration. With the opening of the Clinical Research Center Hanover in 2015, a joint initiative of the federal government and the State of Lower Saxony, the last gap in this area was closed successfully. Hannover Medical School is one of the three largest Lung Transplantation Centers in the world; therefore research in End-Stage Lung Disease is one of the core areas of BREATH. Other closely connected aspects include artificial lung and stem cell research. Extensive preclinical research is conducted in the areas of Infection, Pulmonary Hypertension, Interstitial Lung Diseases and Asthma & Allergies. In the area of basic research, BREATH focuses on the pathobiology of bacterial infections as well as on chronic remodeling processes in the lungs. Further activities aim to better understand the function of the human innate immune system and the control of inflammatory responses in healthy and ill people. In cooperation with the Fraunhofer Institute for Toxicology and Experimental Medicine, research is conducted on the pathophysiology of allergic diseases. The Leibniz University adds expertise in health services research and health-economic aspects as well as in the field of imaging based on laser techniques. The national research network CAPNETZ aims to improve patient-centered care for adults and children with Community-Acquired Pneumonia (CAP), and is also involved in setting up the PROGNOSIS bronchiectasis registry. 

Director of DZL site Hannover (BREATH) is Prof. Dr. Tobias Welte. Head of BREATH’s Office is Dr. Annegret Zurawski.

Contact

DZL manager, BREATH: Dr. Annegret Zurawski
Biomedical Research in Endstage and Obstructive Lung Disease (BREATH)
Medical School Hannover
Zurawski.Annegret[at]mh-hannover.de
Tel.: +49 (0)511 532-5192
Homepage: http://www.breath-hannover.de/